Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital.
Merck & Co. Inc. agreed to acquire privately held VelosBio Inc. for $2.75 billion in cash, in a move that will help strengthen the company’s cancer drug portfolio.
